Crispr Reports Its First Profit In 10 Quarters; Shares Zoom Higher

reported its first profit in 10 quarters on Wednesday, and CRSP stock surged out of a buy zone. This is the company's first earnings report following the historic approval of Casgevy, its gene-edited treatment for sickle cell disease and beta thalassemia. Crispr hasn't yet notched any sales of…#crsp #marketsmithcom #allisongatlin #ibdagatlin #medtronicstockyoyoes #trackandbuy #avoidbiglosses
Source: Reuters: Health - Category: Consumer Health News Source Type: news